CONTENTS

BRAINSTORMS
Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors
Stephen M. Stahl 305

EDITORIAL
The surprising blindness in modern psychiatry: do guidelines really guide?
Pedro Antônio Schmidt do Prado-Lima 312

ORIGINAL RESEARCH
Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis
Jordi Espadañer, Miguel Tuson, José Miguel López-Ibor, Francisco López-Ibor and María Inés López-Ibor 315

Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity
Bernardo Dell’Osso, Cristina Dobrea, Laura Cremaschi, Massimiliano Buoli, Shatali Miller, Terence A. Ketter and A. Carlo Altamura 325

Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control
Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Katly, Linda Snow-Adami, Roger S. McIntyre, Maju Mathews and Carla Hundt 333

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
Domenico De Berardis, Michele Formaro, Federica Vellante, Ilaria Matarazzo, Giampaolo Perna, Giovanni Martinotti and Massimo Di Giannantonio 342

Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older
George G. Nomikos, Dapo Tomori, Wei Zhong, John Affinito and William Palo 348

Posttraumatic stress disorder symptom severity is associated with left hippocampal volume reduction: a meta-analytic study
Michael D. Nelson and Alicia M. Tumpap 363

CORRIGENDA
Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension—CORRIGENDUM
Joseph F. Goldberg, Daisy Ng-Mak, Cynthia Siu, Chien-Chia Chuang, Pithika Rajaprapatna and Antony Leibal 373

The following abstracts were presented as posters at the 2016 NEI Psychopharmacology Congress – CORRIGENDUM
374

Cambridge Core
For further information about this journal please go to the journal web site at:
cambridge.org/cns
Want some CME with that?

STAHLMASTERCCLASS

- An online educational program in core areas of psychiatry with interactive readings, short lectures, animations and case studies
- Self-testing and opportunities to claim formal CME credits, all taken at a self-directed speed
- Written and moderated by experts in the field from the Dr. Stahl's Neuroscience Education Institute and the University of Cambridge

For more information, please go to www.stahlmasterclass.com
BRAINSTORMS

Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors
Stephen M. Stahl 305

EDITORIAL

The surprising blindness in modern psychiatry: do guidelines really guide?
Pedro Antônio Schmidt do Prado-Lima 312

ORIGINAL RESEARCH

Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis
Jordi Espadaler, Miquel Tuson, Jose Miguel Lopez-İbor, Francisco Lopez-İbor and Maria Ines Lopez-İbor 315

Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity
Bernardo Dell’Osso, Cristina Dobrea, Laura Cremaschi, Massimiliano Buoli, Shefali Miller, Terence A. Ketter and A. Carlo Altamura 325

Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control
Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Kelly, Linda Snow-Adami, Roger S. McIntyre, Maju Mathews and Carla Hundt 333

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice
Domenico De Berardis, Michele Fornaro, Laura Orsolini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomeis, Nicola Serroni, Ida De Laurentis, Gabriella Girinelli, Monica Mazza, Alessandro Valchera, Alessandro Carano, Federica Vellante, Ilaria Matarazzo, Giampaolo Perna, Giovanni Martinotti and Massimo Di Giannantonio 342

Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older
George G. Nomikos, Dapo Tomori, Wei Zhong, John Affinito and William Palo 348

Posttraumatic stress disorder symptom severity is associated with left hippocampal volume reduction: a meta-analytic study
Michael D. Nelson and Alecia M. Tumpap 363

CORRIGENDA

Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension—CORRIGENDUM
Joseph F. Goldberg, Daisy Ng-Mak, Cynthia Siu, Chien-Chia Chuang, Krithika Rajagopal and Antony Loebel 373

The following abstracts were presented as posters at the 2016 NEI Psychopharmacology Congress — CORRIGENDUM
374
Editor-in-Chief
Stephen M. Stahl, Adjunct Professor of Psychiatry at the University of California San Diego, USA; Honorary Visiting Senior Fellow at the University of Cambridge, UK.

Field Editors
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Thomas E. Schlaepfer, University Hospital Bonn, Germany
Frank I. Tarazi, Harvard Medical School, USA
Carlos A. Zarate, National Institute of Mental Health, USA

Deputy Editor
Thomas L. Schwartz, SUNY Upstate Medical University at Syracuse, USA

Editorial Board
Maria Conceição do Rosario, University of São Paulo Medical School, Brazil
Jeffrey L. Cummings, Cleveland Clinic, USA
Thilo Deckersbach, Harvard Medical School, USA
Bernardo Dell’Osso, University of Milan, Italy
Koen Dempttenaere, University Psychiatric Center KuLeuven, Belgium
Karen D. Ersche, University of Cambridge, UK
Robert L. Findling, The Johns Hopkins Hospital, USA
Patrick R. Finley, University of California, San Francisco, USA
Mark S. George, Medical University of South Carolina, USA
Ira D. Glick, Stanford University, USA
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Eric Hollander, Albert Einstein College of Medicine and Montefiore Medical Center, USA
Daphne Holt, Harvard Medical School, USA
Peter B. Jones, University of Cambridge, UK
Andres M. Kanner, University of Miami, USA
Antony D. Loebel, New York University School of Medicine, USA
Donatella Marazziti, University of Pisa, Italy
Herbert Y. Meltzer, Northwestern University, USA
Philip Mitchell, University of New South Wales, Australia
Jun Nakamura, University of Occupational and Environmental Health, Japan
Humberto Nicolini, National Institutes of Health, Minister of Health, México
Andrew A. Nierenberg, Harvard Medical School, USA
Stefano Pallanti, University of Florence, Italy
Katharine A. Phillips, Brown University, USA
Diego A. Pizzagalli, Harvard Medical School, USA
Mark H. Pollack, Rush University Medical Center, USA
Mark H. Rapaport, Emory University, USA
Irismar Reis de Oliveira, Universidade Federal da Bahia, Brazil
Trevor W. Robbins, University of Cambridge, UK
Peter P. Roy-Byrne, University of Washington School of Medicine, USA
Barbara J. Sahakian, University of Cambridge, UK
Gerard Sanacora, Yale University School of Medicine, USA
Alan F. Schatzberg, Stanford University School of Medicine, USA
Thomas E. Schlaepfer, University of Bonn, Germany
Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA
Jordan W. Smoller, Harvard Medical School, USA
Dan J. Stein, University of Cape Town (UCT), South Africa
Stephen Strakowski, University of Cincinnati, USA
T. Scott Stroup, Columbia University, USA
Frank I. Tarazi, Harvard Medical School, USA
Michael E. Thase, University of Pennsylvania, USA
Michael Trimble, National Hospital for Neurology, Queen Square, London
Madhukar H. Trivedi, University of Texas Southwestern Medical Center, USA
Karen Dineen Wagner, The University of Texas Medical Branch, USA
Katherine D. Warburton, California Department of State Hospitals, USA
Stephen R. Wisniewski, University of Pittsburgh, USA
Carlos A. Zarate, Jr., National Institute of Mental Health, USA
Joseph Zohar, Tel Aviv University, Israel

Managing Editor
Lisa Arrington, Cambridge University Press (larrington@cambridge.org)
Aims and Scope

CNS Spectrums covers all aspects of the clinical neurosciences, neurotherapeutics and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.

Submitting Manuscripts to CNS Spectrums

All submissions to CNS Spectrums should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated CNS Spectrums ScholarOne Manuscripts website: http://mc.manuscriptcentral.com/cnsspectr

CNS Spectrums will consider and encourage the following types of articles for publication: Reviews—The review article is a comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; Perspectives—The perspective article is a type of review that is a short, focused summary of a single recent advance, a sort of spotlight on the topic, which could be for example, a single point hypothesis or a novel model. It can stimulate debate and new research. Meta-guidelines—A meta-guideline is a “guideline of guidelines” put together by several leading figures in a field in which there are multiple competing guidelines that require synthesis and updating; Original Research—Reports the results of a clinical study and contains original research; the journal will also include Brainstorms and Editorials that shall be commissioned or written by the Editor-in-Chief.

Instructions for Contributors

The Instructions for Contributors are available on the Cambridge Journals Online web site at: http://journals.cambridge.org/CNSifc

Indexing

CNS Spectrums is indexed by Index Medicus/MEDLINE and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

Subscriptions

Institutional print and electronic: £598/$948; Institutional electronic only: £454/$726.

© Cambridge University Press 2017. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: http://www.cambridge.org/rights/permissions/permission.htm. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center http://www.copyright.com, email: info@copyright.com.

Rights & permissions requests can be applied for online within each article by clicking “Request Permissions” within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

CNS Spectrums (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

Postmaster


Online availability

CNS Spectrums is hosted on the Cambridge Core service at cambridge.org/cns

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: http://journals.cambridge.org/

Reprint and Advertising Sales

Inquiries for bulk reprint sales should be sent to USReprints@cambridge.org. Advertising inquiries should be sent to M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009; Phone: 856-768-9360; Fax: 856-753-0064; Email: mjmrvica@mrvica.com.